Previous close | 1.3900 |
Open | 1.3700 |
Bid | 0.0000 x 42300 |
Ask | 0.0000 x 45100 |
Day's range | 1.3500 - 1.4600 |
52-week range | 1.1200 - 2.5450 |
Volume | |
Avg. volume | 18,866,833 |
Market cap | 3.051B |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4100 |
Earnings date | 08 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.38 |
Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.
XWELL, Inc. Brands XWELL, Inc. Brands Airport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue GrowthNaples Wax Center Acquisition Accelerates Future Off-Airport Growth OpportunitiesFurther Airport Spa Expansion Internationally NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023. Financial and Business Highlights: The Compa
Foremost Farms USA, a world-class producer of cheese, butter, and dairy ingredients supplied to national and international markets, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to use advances in biotechnology to enable domestic, sustainable biomanufacturing of materials from dairy co-products to benefit the environment, family farms and the dairy industry as a whole.